Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Symptoms and General Pathology

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Recurrence

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

in patients with a NSCLC KRAS-other (non-G12V) tumor

in patients with a NSCLC BRAF-V600E tumor

in patients with a NSCLC BRAF-non-V600E tumor

avutometinib (VS-6766)

avutometinib (VS-6766) and Defactinib

Ross Camidge, MD, PhD

MD Verastem

This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy or VS-6766 in combination with defactinib in subjects with recurrent Non-small cell lung cancer.

This is a multicenter, open-label Phase 2 study designed to evaluate safety and tolerability and efficacy of avutometinib (VS-6766) versus avutometinib (VS-6766) in combination with defactinib in subjects with KRAS and BRAF mutant NSCLC following treatment with an appropriate platinum-based regimen and an approved immune checkpoint inhibitor (CPI).

A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)

Confirmed overall response rate per RECIST 1.1

Adverse events (AEs), serious AEs (SAEs), vital signs, physical examinations, clinical laboratory values, and tolerability (dose interruptions/reductions)

Proportioned subjects achieving a CR or PR as assess by the investigator

Time of first response to PD as assessed by the IRC

CR and PR stable disease as assessed by the IRC

From the time of first dose of study intervention to PD or death from any cause

From time of first dose of study intervention to death

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer	NCT04620330	Non Small Cell ... KRAS Activating...	avutometinib (V... avutometinib (V...	18 Years -	Verastem, Inc.
A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer	NCT04620330	Non Small Cell ... KRAS Activating...	avutometinib (V... avutometinib (V...	18 Years -	Verastem, Inc.

Spots Global Cancer Trial Database for v600e

Every month we try and update this database with for v600e cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for v600e

Every month we try and update this database with for v600e cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for v600e cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.